Abstract | BACKGROUND AND PURPOSE: METHODS: RESULTS: During a mean of 2.0 years of follow-up, 154 intracranial hemorrhages occurred in 153 participants: 46% intracerebral (49% mortality), 45% subdural (24% mortality), and 8% subarachnoid (31% mortality). The rates of intracranial hemorrhage were 0.76%, 0.31%, and 0.23% per year among those assigned to warfarin, dabigatran 150 mg, and dabigatran 110 mg, respectively (P<0.001 for either dabigatran dose versus warfarin). Fewer fatal intracranial hemorrhages occurred among those assigned dabigatran 150 mg and 110 mg (n=13 and n=11, respectively) versus warfarin (n=32; P<0.01 for both). Fewer traumatic intracranial hemorrhages occurred among those assigned to dabigatran (11 patients with each dose) compared with warfarin (24 patients; P<0.05 for both dabigatran doses versus warfarin). Independent predictors of intracranial hemorrhage were assignment to warfarin (relative risk, 2.9; P<0.001), aspirin use (relative risk, 1.6; P=0.01), age (relative risk, 1.1 per year; P<0.001), and previous stroke/ transient ischemic attack (relative risk, 1.8; P=0.001). CONCLUSIONS:
|
Authors | Robert G Hart, Hans-Christoph Diener, Sean Yang, Stuart J Connolly, Lars Wallentin, Paul A Reilly, Michael D Ezekowitz, Salim Yusuf |
Journal | Stroke
(Stroke)
Vol. 43
Issue 6
Pg. 1511-7
(Jun 2012)
ISSN: 1524-4628 [Electronic] United States |
PMID | 22492518
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Benzimidazoles
- beta-Alanine
- Warfarin
- Dabigatran
|
Topics |
- Aged
- Anticoagulants
- Atrial Fibrillation
(drug therapy, epidemiology, mortality)
- Benzimidazoles
(administration & dosage, adverse effects)
- Dabigatran
- Female
- Humans
- International Normalized Ratio
(adverse effects)
- Intracranial Hemorrhages
(chemically induced, diagnostic imaging, mortality)
- Male
- Radiography
- Risk Factors
- Warfarin
(administration & dosage, adverse effects)
- beta-Alanine
(administration & dosage, adverse effects, analogs & derivatives)
|